
Group in West Dawson, Yukon, seeks association status to support grassroots emergency services
During the summer months a ferry can bring ambulances to the subdivisions of West Dawson and Sunnydale. But when the river is freezing and breaking up, ambulances can't get there. Darker days also make medevac flights more challenging.
David Curtis, a spokesperson for the unnamed group, said there have been times when members have had to transport individuals across the river by snowmobile because the river wasn't fully frozen. They also tend to wounds, fractures, or any other calls they have capacity to handle.
Curtis said they need more resources for when they're the first to respond to emergencies.
"We're not acting in an official capacity that way," Curtis said. "We're acting as Good Samaritans. We've been doing this sort of ad hoc and it's been going good but we could do a lot better job."
Defibrillators, spine boards and medical kits
Curtis said the group has submitted its application for association status to Yukon's Department of Community Services and he hopes to hear back soon.
While he waits for that – he said he's been talking with Yukon's Emergency Medical Services (EMS) to see how it can support them ahead of this year's freeze up.
Curtis said they're in preliminary discussions with Yukon EMS about getting an additional defibrillator and pads, as well as a spine board and medical kits. He said Yukon EMS "expressed very clearly" that it wasn't in the position to give his group expensive equipment just because he thinks they need it.
"They need to have a more official knowledge too that the equipment will be maintained, and supplies are going to be kept up and up to date, and everything is looked after properly."
Curtis is hoping to receive the designation and equipment before this year's freeze up.
Ryan Soucy, the acting chief of Yukon's EMS, confirmed his department was in preliminary discussions with Curtis – but without being a recognized society or association, he said there's a lot of red tape to go through before the department can give Curtis the support he and his group are hoping for.
"If you look at the Canadian Ski Patrol society you know we're able to work with them," Soucy said. "They're providing care at Mount Sima as well as the trails of Mount Mac. So we can actually work with them a bit more other than just general public."
Soucy said it is encouraging to see members of the public take interest in helping provide care for their neighbours and said volunteering with Yukon EMS could open the doors to training opportunities to better serve their community.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
20 minutes ago
- CTV News
Bruce Power gets funding to increase cancer-fighting isotope production
Production of medical isotopes at the Bruce Power Nuclear Plant near Kincardine, Ont. is seen in this undated image. (Source: Bruce Power) Domestic supply chains for medical isotope production in Canada has received a boost from the federal government. Announced on Tuesday, the investment of up to $35 million over five years will support the project at the Bruce Power Nuclear Plant facility in Tiverton, Ont. According to the federal government, this next phase will see the installation of a second isotope production system (IPS) at Bruce Power's CANDU Unit 6 reactor, which will allow for a significant increase in the plant's ability to produce the medical isotope lutetium-177, used in targeted cancer therapies. 'Canada is proud to support research and development on medical isotopes... With this investment, we will continue to play a leading role in the global supply of medical isotopes and drive the creation of innovative health care treatments for Canadians,' said Minister of Health, Marjorie Michel. BRUCE POWER - ISOTOPES - AUG 2025 Officials make an announcement at Bruce Power on Aug. 19, 2025. (Scott Miller/CTV News London) Medical isotopes are used by medical professionals to diagnose and treat health conditions such as heart disease and cancer. Medical isotopes are produced using two overarching technologies: nuclear reactors and particle accelerators. There are currently global constraints on the supply of medical isotopes, and according to the government, the CMIE will ensure that Canada remains at the forefront of nuclear medicine innovation.


CTV News
20 minutes ago
- CTV News
Swim advisory posted for popular Barrie beach due to high bacteria levels
A swim advisory is in effect at Centennial Beach after water test results raised concerns about safety. The Simcoe Muskoka District Health Unit issued the recommendation based on samples taken on Monday, indicating significant bacteria levels. An advisory is a warning to swimmers, but not a beach closure. Advisories are issued when the bacteria levels exceed those considered safe by the health unit. City staff have posted advisory signs, warning visitors to avoid swimming until further notice. Additional water samples are being taken Monday, and the city says it will provide an update as soon as new results are available from public health officials.


Globe and Mail
an hour ago
- Globe and Mail
Health Canada approves Ozempic to reduce kidney decline in people with Type 2 diabetes
Health Canada has approved Ozempic to reduce the risk of further kidney decline among patients with Type 2 diabetes. Between 30 and 50 per cent of people with Type 2 diabetes develop some form of chronic kidney disease. An international clinical trial, called FLOW, showed the risk of kidneys significantly deteriorating or failing was 24 per cent lower in patients taking Ozempic compared to those taking a placebo injection. The patients taking the drug were also less likely to die from cardiovascular disease – another condition that affects many patients with diabetes. The study, funded by Ozempic manufacturer Novo Nordisk, was peer-reviewed and published in the New England Journal of Medicine last year and contributed to Health Canada's decision. Generic version of Ozempic, Wegovy to launch in Canada by Hims & Hers Dr. David Cherney, a nephrologist at Toronto General Hospital, helped lead the Canadian part of the trial and says the results show it's possible to reduce the loss of kidney function before patients need dialysis or a kidney transplant. 'What my patients are scared of is dialysis – dialysis or a transplant,' said Cherney, who is also a senior scientist at the Toronto General Hospital Research Institute, in an interview. 'I can reasonably reduce that risk and thereby reduce their anxiety and fear of serious, serious complications. Not to mention all the cardiovascular disease, which patients are also extremely afraid of.' Dr. Ehud Ur, an endocrinologist in Vancouver who was not involved in the study, said the results are credible and that Health Canada's approval of Ozempic to help prevent kidney decline is 'great news.' 'The prevention of kidney disease is a very important goal in the management of patients with Type 2 diabetes and this is another tool,' said Ur, who is a professor of endocrinology and metabolism at the University of British Columbia. Ozempic is the brand name of an injectable dose of semaglutide, a glucagon-like peptide-1 (GLP-1) hormone. Ozempic was first approved in Canada as a diabetes medication because it reduces blood sugar. It can also decrease appetite and has been approved as a weight-loss drug for people with obesity at a higher dose under the brand name Wegovy, which is also manufactured by Novo Nordisk. In an e-mail, Health Canada confirmed to The Canadian Press that on Aug. 13, it had approved Ozempic 'to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease and cardiovascular death in adults with Type 2 diabetes and chronic kidney disease.' Glomerular filtration rate is a measure that shows how well the kidneys are filtering out waste and excess water. Semaglutide, or Ozempic, reduces symptoms of feared diabetes complication, study finds Ozempic is the first GLP-1 drug approved in Canada to protect both kidneys and the heart in patients with Type 2 diabetes, said Ur, noting that the cardiovascular benefits of semaglutide have been extensively studied. 'The benefit of Ozempic is that you also get weight loss, which is a very important goal for most people (with Type 2 diabetes). That's a very exciting combination,' he said. Some people experience gastrointestinal side effects when they take Ozempic, Ur said, including nausea, vomiting, constipation and diarrhea. More severe complications can include gall bladder inflammation and pancreatitis, but most side effects are minor, he said. The benefit of slowing or stopping progressive kidney disease in people with diabetes would outweigh the risks of minor side effects, Ur said. The FLOW trial was conducted in 28 countries, including Canada. The researchers randomized 3,533 people with diabetes and chronic kidney disease to either receive Ozempic or a placebo. The study was conducted between 2019 and early 2024. Participants were followed for an average of 3.4 years to monitor for 'major kidney disease events,' including kidney failure leading to dialysis or transplantation, a 50-per-cent reduction in kidney function measured by glomerular filtration rate, or death from kidney-related or cardiovascular causes. The Ozempic or placebo doses were given to participants on top of other medications they were taking, including drugs to control blood pressure and blood sugar. Although reducing blood pressure and blood sugar have beneficial effects for the kidneys, Cherney said Ozempic appeared to have an additional positive impact on kidney function and future research can help pinpoint how that works. 'Another weapon against kidney disease is incredibly powerful. And these medicines will often turn patients around who are doing very poorly because it addresses so many different issues – the kidney, the cardiovascular, the metabolic, and the weight,' said Cherney. Ur said it's possible Ozempic could play a role in reducing inflammation in the kidneys and that might be one explanation for its positive effect. Regardless of the reason for its effectiveness, he said the FLOW trial and Health Canada's approval reinforces the importance of using the drug 'relatively early in the disease process' to minimize kidney damage in people with Type 2 diabetes.